Dr.KelvinChong Hong Kong, China

Dr.KelvinChong
Prof Kelvin Chong is the first full-time academic in orbital and oculoplastic surgeries(OOPS) in Hong Kong. He is the Clinical Associate Professor, Chief of Orbital and Oculoplastic Surgery, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong(CUHK). He serves as the Director of Eye Centre, CUHK Medical Centre and Honorary Consultant Ophthalmologist of 6 public hospitals. His research focuses on thyroid eye disease(TED), IgG4-related ophthalmic disease, and minimally invasive OOPS. He pioneered the first thyroid eye clinic and image-guided medical and surgical decompression for TED. He led multiple randomized clinical trials(RCT), introduced Mohs micrographic surgeries, sentinel lymph node biopsy, endoscopic navigation, 3D-printing, and dacryoendoscopy to HK. He published over 120 peer-reviewed articles, 10 book chapters, 15 patents, and delivered over 180 invited & keynote lectures. He trained 16 postgraduate students, 17 OOPS fellows and obtained >US$3.5 million as Principal Investigator of 26 competitive research grants. He was bestowed 2 research, 3 invention, 7 conference presentation, 9 service and achievement awards. He co-founded and presided the Hong Kong Society of Ophthalmic Plastic and Reconstructive Surgery(HKSOPRS) and is currently the President-elect of the Asia Pacific Society of Ophthalmic Plastic and Reconstructive Surgeries(APSOPRS).

20 MARCH

Time Session
13:50
15:20
[Symposium] Thyroid (2)
Thyroid Eye Disease Management
  • Novel Biomarkers and Treatment Strategies in Thyroid Eye Disease
    Chia-Hung LinTaiwan Speaker Novel Biomarkers and Treatment Strategies in Thyroid Eye Disease
  • Management of Thyroid Eye Disease: Insights from Clinical Experience and MRI Findings in Japan
    Ichiro YamauchiJapan Speaker Management of Thyroid Eye Disease: Insights from Clinical Experience and MRI Findings in JapanIn Japan, disease activity of thyroid eye disease (TED) is commonly assessed using magnetic resonance imaging (MRI) in addition to clinical activity score (CAS). Recently, we proposed an MRI-guided categorization of active moderate-to-severe TED based on our retrospective data. We retrospectively analyzed TED cases treated at our department between 2015 and 2022 with a combination of daily steroid pulse therapy and orbital radiation. Among 44 cases with diplopia, we classified 17 cases as severe (diplopia in the primary position) and 27 as non-severe (diplopia only in non-primary positions). The severe group was older (median 67 years) and had lower TSAb titers (median 324%) compared to the non-severe group (median 56 years, median TSAb 2443%). CAS was similar between the groups. MRI revealed that proptosis was more pronounced in the non-severe group (median 21.4 mm) than in the severe group (median 17.5 mm), whereas the difference in proptosis between eyes was larger in the severe group (median 2.0 mm) than in the non-severe group (median 0.9 mm). High signal intensity of orbital fat on STIR sequence was more frequently observed in the non-severe group (68.2%) than in the severe group (20.0%). These findings suggest that TED patients with severe diplopia are characterized by older age, lower TSAb titers, and greater asymmetry in proptosis. In contrast, CAS and STIR signal intensity of orbital fat were not indicative of severity. In this context, severe diplopia often develops despite low CAS and mild proptosis. We also present our clinical experience with teprotumumab, an anti–IGF-1 receptor antibody. Since its launch in Japan in 2024, we have treated several patients with severe TED, the majority of whom showed remarkable improvement in clinical features. However, adverse effects such as hearing impairment and hyperglycemia were occasionally observed, highlighting the importance of appropriate management. In conclusion, MRI-guided evaluation provides valuable insights for individualized management of TED. Evidence regarding the efficacy of teprotumumab remains limited in the subtype characterized by severe diplopia, which often presents with low CAS and mild proptosis. The MRI-guided approach may help clinicians select optimal therapeutic strategies, including steroid pulse therapy, teprotumumab, and other emerging agents.
  • An Update on Thyroid Eye Disease Management
    Kelvin ChongHong Kong, China Speaker An Update on Thyroid Eye Disease Management
101